NASDAQ: SNYSanofi Stock
$48.48+0.26 (+0.54%)
Updated Sep 22, 2021
SNY Price
$48.48
Fair Value Price
N/A
Market Cap
$121.27B
52 Week Low
$44.76
52 Week High
$54.26
P/E
8.19x
P/B
1.6x
P/S
2.67x
PEG
N/A
Dividend Yield
3.93%
Revenue
$45.02B
Earnings
$15.02B
Gross Margin
67.5%
Operating Margin
38.85%
Profit Margin
33%
Debt to Equity
0.82
Operating Cash Flow
$9B
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
High
Medium
Low
53
Industry average
Reasons for this score
SNY is good value based on its earnings relative to its share price (8.19x), compared to the US market average -10.34x)
Valuation
SNY is good value based on its earnings relative to its share price (8.19x), compared to the US Drug Manufacturers - General industry average (21.92x)
Valuation
SNY is good value based on its book value relative to its share price (1.6x), compared to the US Drug Manufacturers - General industry average (5.12x)
Valuation
SNY News
Valuation
SNY fair value
Fair Value of SNY stock based on Discounted Cash Flow (DCF)
Price
$48.48
Fair Value
$51.78
Undervalued by
6.37%
SNY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
8.19x
Industry
21.92x
Market
-10.34x
SNY is good value based on its earnings relative to its share price (8.19x), compared to the US market average -10.34x)
Valuation
SNY is good value based on its earnings relative to its share price (8.19x), compared to the US Drug Manufacturers - General industry average (21.92x)
Valuation
SNY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.6x
Industry
5.12x
SNY is good value based on its book value relative to its share price (1.6x), compared to the US Drug Manufacturers - General industry average (5.12x)
Valuation
SNY's financial health
Profit margin
Revenue
$45.6B
Net Income
$15.0B
Profit Margin
33%
SNY's Earnings (EBIT) of $17.49B can safely cover interest payments on company debt ($28.52B)
Financials
SNY's profit margin has increased (+25.5%) in the last year from (7.5%) to (33%)
Financials
Assets to liabilities
Assets
$139.7B
Liabilities
$62.7B
Debt to equity
0.38
SNY's short-term assets ($40.61B) exceed its short-term liabilities ($23.19B)
Financials
SNY's short-term assets ($40.61B) exceed its long-term liabilities ($38.72B)
Financials
SNY's debt has increased relative to shareholder equity (0.82), over the past 5 years ago (0.76)
Financials
SNY's debt to equity ratio (0.82) is considered high
Financials
Cash flow
Operating
$9.1B
Investing
$4.4B
Financing
-$7.9B
SNY's operating cash flow ($8.97B) is sufficient to service the company's debt ($28.52B)
Financials
Sanofi Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.